FTREFortrea Holdings Inc.
Price
+106%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality shaky, hard red flags, undemanding price, growth steady, the market undecided.
Fortrea Holdings Inc. is a leading global contract research organization (“CRO”), providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology and medical device customers. We provide phase I through IV clinical trial management, clinical pharmacology, and consulting services for our customers. For more than 30 years, we have supported our global pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas, providing agile delivery models that include Full Service, Functional Service Provider (“FSP”), and Hybrid structures.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Fortrea Holdings Inc. (FTRE) reported revenue of $678M in Q2 2026 (quarter ended Jun 30, 2026), down 4.5% from the same quarter a year earlier. That came with a gross margin of 21% and net loss of $13M. For the full year FY2025, revenue was $2.72B (+1.0% year on year) and net income −$986M. Its largest region in Q2 2026 was North America at $320M, 47% of the disclosed total, ahead of Europe at 32%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 30, 2026Appointment of Chief Accounting Officer Effective October 5, 2026, Fortrea Holdings Inc. (the “Company”) appointed Carrie Russell as its Chief Accounting Officer.Director or officer change · Form 8-K
- Sep 10, 2026On September 9, 2026, the Board of Directors (the “Board”) of Fortrea Holdings, Inc. (the “Company”) reinstated Jason Knoblauch as Chief Financial Officer and designated Mr. Knoblauch as principal financial officer of the Company.Director or officer change · Form 8-K
- Jul 29, 2026On July 27, 2026, the Board of Directors of the Company (the “Board”) appointed David Smith, a current director on the Board, to act as Interim Chief Financial Officer and principal financial officer (“Interim CFO”)Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $678.2MThe company’s own SEC segment disclosure.
- North America$319.7M47%
- Europe$219.7M32%
- Other Geographical Areas$138.8M20%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.